- Home
- CLVT vs DYN Comparison
CLVT vs DYN Comparison
Compare CLVT & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLVT
- DYN
- Stock Information
- Founded
- CLVT 2016
- DYN 1984
- Country
- CLVT United Kingdom
- DYN United States
- Employees
- CLVT N/A
- DYN N/A
- Industry
- CLVT EDP Services
- DYN Medicinal Chemicals and Botanical Products
- Sector
- CLVT Technology
- DYN Health Care
- Exchange
- CLVT Nasdaq
- DYN Nasdaq
- Market Cap
- CLVT 2.8B
- DYN 2.6B
- IPO Year
- CLVT N/A
- DYN 2020
- Fundamental
- Price
- CLVT $3.99
- DYN $9.91
- Analyst Decision
- CLVT Hold
- DYN Strong Buy
- Analyst Count
- CLVT 4
- DYN 12
- Target Price
- CLVT $5.83
- DYN $47.73
- AVG Volume (30 Days)
- CLVT 5.1M
- DYN 2.1M
- Earning Date
- CLVT 04-29-2025
- DYN 05-01-2025
- Dividend Yield
- CLVT N/A
- DYN N/A
- EPS Growth
- CLVT N/A
- DYN N/A
- EPS
- CLVT N/A
- DYN N/A
- Revenue
- CLVT $2,556,700,000.00
- DYN N/A
- Revenue This Year
- CLVT N/A
- DYN N/A
- Revenue Next Year
- CLVT $0.75
- DYN N/A
- P/E Ratio
- CLVT N/A
- DYN N/A
- Revenue Growth
- CLVT N/A
- DYN N/A
- 52 Week Low
- CLVT $3.83
- DYN $8.94
- 52 Week High
- CLVT $7.77
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- CLVT 38.84
- DYN 33.59
- Support Level
- CLVT $3.83
- DYN $10.72
- Resistance Level
- CLVT $4.16
- DYN $12.00
- Average True Range (ATR)
- CLVT 0.19
- DYN 0.80
- MACD
- CLVT 0.01
- DYN -0.13
- Stochastic Oscillator
- CLVT 20.95
- DYN 25.06
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.